Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Victoria Harries, Jyothi Abraham, Lupesina Vesi, Aniva Reupena, Kima Faaselele-Savusa, Rachel L Duckham, Richard Bribiescas, Nicola Hawley
BACKGROUND: Current research suggests that energy transfer through human milk influences infant nutritional development and initiates metabolic programming, influencing eating patterns into adulthood. To date, this research has predominantly been conducted among women in high income settings and/or among undernourished women. We will investigate the relationship between maternal body composition, metabolic hormones in human milk, and infant satiety to explore mechanisms of developmental satiety programming and implications for early infant growth and body composition in Samoans; a population at high risk and prevalence for overweight and obesity...
2024: PloS One
#2
JOURNAL ARTICLE
Dong An, Dongmei Meng, Rui Yang, Ying Yang, Junhong Yang, Weiwei Gao, Jiayi Zhang, Wen Chen, Wanqi Zhang
Iodine is a trace element necessary for synthesizing thyroid hormones. It is especially crucial for the neurodevelopment and intellectual development of children. Preschool-age children admitted to the hospital tend to have more fragile physical and mental health, but few studies demonstrate their iodine status. Our study aimed to investigate the iodine status of hospitalized and healthy preschool-age children and to explore the factors influencing them. From January to December 2021, 426 children aged 3-6 years were admitted to the respiratory department for pneumonia, bronchopneumonia, or bronchiectasis, but they could eat normally and were recruited as hospitalized children...
May 10, 2024: Biological Trace Element Research
#3
JOURNAL ARTICLE
Rasha A Thabet, Eman M Sherif, Ahmed O Abd ElAal, Rana A Mahmoud
BACKGROUND: This study aimed to assess the anthropometric measures and pubertal growth of children and adolescents with Type 1 diabetes mellitus (T1DM) and to detect risk determinants affecting these measures and their link to glycemic control. PATIENTS AND METHODS: Two hundred children and adolescents were assessed using anthropometric measurements. Those with short stature were further evaluated using insulin-like growth factor 1 (IGF-1), bone age, and thyroid profile, while those with delayed puberty were evaluated using sex hormones and pituitary gonadotropins assay...
May 9, 2024: BMC Endocrine Disorders
#4
JOURNAL ARTICLE
Vera Chesnokova, Svetlana Zonis, Tugce Apaydin, Robert Barrett, Shlomo Melmed
DNA damage-induced senescence is initially sustained by p53. Senescent cells produce a senescence-associated secretory phenotype (SASP) that impacts the aging microenvironment, often promoting cell transformation. Employing normal non-tumorous human colon cells (hNCC) derived from surgical biopsies and three-dimensional human intestinal organoids, we show that local non-pituitary growth hormone (npGH) induced in senescent cells is a SASP component acting to suppress p53. npGH autocrine/paracrine suppression of p53 results in senescence evasion and cell-cycle reentry, as evidenced by increased Ki67 and BrdU incorporation...
May 9, 2024: Aging Cell
#5
JOURNAL ARTICLE
Chenyang Li, Xi Wang, Min Nie, M A O Jiangfeng, Xueyan Wu
BACKGROUND: There have been rare data in Letrozole for height promotion in girls.This study aims to clarify the efficacy and safety of combination therapy with human recombinant growth hormone, GnRHa and letrozole in improving the height of girls with short stature and advanced bone age. METHODS: This is a retrospective record-based study. Follow-up was conducted on girls with short stature who received rhGH,GnRHa and letrozole treatment at outpatient clinics in our hospital...
May 7, 2024: Endocrine Practice
#6
MULTICENTER STUDY
Javier Retamales, Adrián Daneri-Navarro, Nora Artagaveytia, Daniela Alves da Quinta, Eliana Abdelhay, Osvaldo L Podhajcer, Carlos Velázquez, Diego Giunta, Susanne Crocamo, Adriana Garibay-Escobar, Alicia Del Toro-Arreola, Robinson Rodriguez, Marta Aghazarian, Elsa Alcoba, Isabel Alonso, Renata Binato, Alicia I Bravo, Juan Canton-Romero, Dirce M Carraro, Mónica Castro, Juan Castro-Cervantes, Sandra Cataldi, Natalia Camejo, Laura Cortes-Sanabria, Maria Flores-Marquez, Guillermo Laviña, Eduardo Musetti, Benedicta Caserta, Mauricio Cerda, Alicia Colombo, Raul Delgadillo-Cristerna, Marisa Dreyer Breitenbach, Elmer Fernandez, Jorge Fernandez, Ramon Franco-Topete, Carolina Gabay, Fancy Gaete, Jorge Gamboa, Ricardo García-Gaeta, Mariana Gomez Del Toro, Leivy P Gonzalez-Ramirez, Marisol Guerrero, Manuel Herrera-Miramontes, Alejandra Lopez-Vasquez, Silvina Maldonado, Andrés Morán-Mendoza, Gilberto Morgan-Villela, Maria Aparecida Nagai, Nancy Navarro-Ruiz, Antonio Oceguera-Villanueva, Miguel Angel Ortiz, Jael Quintero, Antonio Quintero-Ramos, Gladys Ramirez-Rosales, Maritza Ramos-Ramirez, Marcia Maria Chiquitelli Marques, Ernesto Rivera Claisse, Diego Rodriguez-Gonzalez, Ana Romero-Gomez, Cristina Rosales, Efraín Salas-Gonzalez, Verónica Sanchotena, Laura Segovia, Aída A Silva-García, Olivia Valenzuela-Antelo, Laura Venegas-Godinez, Livia Zagame, Jorge Gomez, Andrea S Llera, Bettina Müller
PURPOSE: Breast cancer mortality rates in Latin America (LA) are higher than those in the United States, possibly because of advanced disease presentation, health care disparities, or unfavorable molecular subtypes. The Latin American Cancer Research Network was established to address these challenges and to promote collaborative clinical research. The Molecular Profiling of Breast Cancer Study (MPBCS) aimed to evaluate the clinical characteristics and treatment outcomes of LA participants with locally advanced breast cancer (LABC)...
May 2024: JCO global oncology
#7
JOURNAL ARTICLE
Subhas Konar, Ujwal Yeole, Dhaval Shukla, Dhananjaya I Bhat, Nishanth Sadashiva, Bhagavatula Indira Devi
Background and Objective Surgery is the treatment of choice for growth hormone (GH)-secreting pituitary adenoma. The remission of random GH depends on various factors. We aimed to evaluate the predictors related to remission of random GH following surgical treatment. Methods We collected the data retrospectively from the chart review from a single unit of neurosurgery. The diagnostic criteria for remission were a random GH < 1 ng/mL or nadir GH < 0.4 ng/mL after an oral glucose tolerance test...
June 2024: Journal of Neurological Surgery. Part B, Skull Base
#8
JOURNAL ARTICLE
Roy Gomez, Vaman Khadilkar, Jayashri Shembalkar, Der-Ming Chu, Cheol Woo Ko, Michael P Wajnrajch, Ronnie Wang
OBJECTIVES: Somatrogon is a long-acting recombinant human growth hormone used to treat patients with paediatric growth hormone deficiency (pGHD). This global phase 3 study compared the efficacy and safety of once-weekly somatrogon with once-daily somatropin in children with GHD. METHODS: Prepubertal patients were randomized 1:1 to once-weekly somatrogon (0.66 mg/kg/week) or once-daily somatropin (0.24 mg/kg/week) for 12 months. The primary endpoint was height velocity (HV) at month 12; secondary endpoints included HV at month 6 and change in height standard deviation score (SDS) at months 6 and 12 and insulin-like growth factor 1 (IGF-1) SDS...
May 9, 2024: Journal of Pediatric Endocrinology & Metabolism: JPEM
#9
JOURNAL ARTICLE
Xitong Liu, Na Li, Dongyang Wang, Wen Wen, Li Tian, Hanying Zhou, Ben W Mol, Juanzi Shi, Tao Wang
BACKGROUND: Growth hormone (GH) has been proposed as an adjunct in in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles, especially in women with poor ovarian response. However, it is unclear whether GH supplementation is effective in women with poor embryonic development in the previous IVF cycle. The aim of this study was to evaluate the effectiveness of GH supplementation in IVF/ICSI cycles in women with poor embryonic development in the previous cycle. METHODS: This is a retrospective cohort study from a public fertility center in China, in which we performed propensity score-matching (PSM) for female age and AFC in a ratio of 1:1...
May 7, 2024: Reproductive Biology and Endocrinology: RB&E
#10
JOURNAL ARTICLE
Marta Araujo-Castro, Betina Biagetti, Edelmiro Menedez-Torre, Iría Novoa-Testa, Fernando Cordido, Eider Pascual-Corrales, Víctor Rodríguez Berrocal, Fernando Guerrero-Pérez, Almudena Vicente, Juan Carlos Percovich Hualpa, Rogelio Garcia Centeno, Laura González Fernández, María Dolores Ollero García, Ana Irigaray Echarri, María Dolores Moure Rodríguez, Cristina Novo-Rodríguez, María Calatayud, Rocío Villar, Ignacio Bernabéu, Cristina Alvarez-Escola, Pamela Benítez Valderrama, Carmen Tenorio, Pablo Abellán Galiana, Eva Venegas, Inmaculada González-Molero, Pedro Iglesias, Concepción Blanco-Carrera, Fernando Vidal-Ostos De Lara, Paz de Miguel Novoa, Elena López Mezquita, Felicia Alexandra Hanzu, Iban Aldecoa, Silvia Aznar, Cristina Lamas, Anna Aulinas, Anna Queralt Asla, Paola Gracia Gimeno, José María Recio Córdova, Mariola Aviles, Diego Asensio-Wandosel, Miguel Sampedro-Núñez, Rosa Camara, Miguel Paja Fano, Ignacio Ruz-Caracuel, Carmen Fajardo, Mónica Marazuela, Manel Puig-Domingo
AIM: To evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH/PRL-Pit-NET) and compare to those caused by a GH-Pit-NET. METHODS: A multicenter retrospective study of patients with acromegaly on treatment with pasireotide or pegvisomant. Patients were classified in two groups: GH/PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were >200 ng/dL regardless of the PRL-IHC; and GH-Pit-NETs when the previously mentioned criteria were not met...
May 1, 2024: Endocrine-related Cancer
#11
REVIEW
Zahra Hasanpour Segherlou, Mahdieh Shakeri-Darzekonani, Armin Khavandegar, Sara Stephenson, Kimberly Ciccone, Forough Masheghati, Mohammad Reza Hosseini Siyanaki, Mac Lyerly, Brandon Lucke-Wold
INTRODUCTION: Intracranial aneurysms (IAs) occur in 3-5% of the general population and are characterized by localized structural deterioration of the arterial wall with loss of internal elastic lamina and disruption of the media. The risk of incidence and rupture of aneurysms depends on age, sex, ethnicity, and other different factors, indicating the influence of genetic and environmental factors. When an aneurysm ruptures, there is an estimated 20% mortality rate, along with an added 30-40% morbidity in survivors...
May 7, 2024: Expert Review of Endocrinology & Metabolism
#12
JOURNAL ARTICLE
María Güemes, Álvaro Martín-Rivada, Beatriz Corredor, Patricia Enes, Sandra Canelles, Vicente Barrios, Jesús Argente
CONTEXT: Anomalies in the growth hormone (GH)/insulin-like growth factor (IGF) axis, are common in children with type 1 diabetes mellitus (T1DM), even in those reaching a normal or near-normal final height. However, concentrations of the IGF bioavailability regulatory factors (pappalysins [PAPP-As] and stanniocalcins [STCs]) have not been reported in children with T1DM. OBJECTIVE: To determine serum concentrations of PAPP-As and STCs in children at diagnosis of T1DM and after insulin treatment and the correlation of these factors with other members of the GH/IGF axis, beta-cell insulin reserve, auxology, and nutritional status...
April 6, 2024: Journal of the Endocrine Society
#13
JOURNAL ARTICLE
Jingjing Cai, Xiangmin Luo, Zhengyao Wang, Zixuan Chen, Donghong Huang, Hui Cao, Jing Chen, Jinxiang Wu
BACKGROUND: Polycystic ovary syndrome (PCOS) is main cause of anovulatory infertility in women with gestational age. There are currently four distinct phenotypes associated with individualized endocrinology and metabolism. Growth differentiation factor 9 (GDF9) is a candidate as potential biomarker for the assessment of oocyte competence. The effect on oocyte capacity has not been evaluated and analyzed in PCOS phenotypes. OBJECTIVE: We aimed to screen the expression levels of GDF9 in mature follicles of women with controlled ovarian hyperstimulation (COS) with different PCOS phenotypes...
May 15, 2024: Heliyon
#14
JOURNAL ARTICLE
Lori R Bernstein, Amelia C L Mackenzie, Charles L Chaffin, Se-Jin Lee, Duane C Kraemer, Istvan Merchenthaler
BACKGROUND: Elevated FSH often occurs in women of advanced maternal age (AMA, age ≥ 35) and in infertility patients undergoing controlled ovarian stimulation (COS). There is controversy on whether high endogenous FSH contributes to infertility and whether high exogenous FSH adversely impacts patient pregnancy rates. METHODS: The senescence-accelerated mouse-prone-8 (SAMP8) model of female reproductive aging was employed to assess the separate impacts of age and high FSH activity on the percentages (%) of viable and mature ovulated oocytes recovered after gonadotropin treatment...
May 6, 2024: Reproductive Biology and Endocrinology: RB&E
#15
JOURNAL ARTICLE
Yuki Kawashima-Sonoyama, Keisuke Wada, Kei Yamamoto, Masanobu Fujimoto, Noriyuki Namba, Takeshi Taketani
Short stature with IGF-1 receptor (IGF1R) gene alteration is known as small-for-gestational-age (SGA) short stature with elevated serum IGF1 levels. Its prevalence and clinical characteristics remain unclear. No adapted treatment is available for short stature related to IGF1R gene alteration in Japan, and genetic testing is not yet widely accessible. We investigated short stature with IGF1R gene alterations and analyzed the clinical data of 13 patients using the results of questionnaires issued to the Japanese Society for Pediatric Endocrinology...
May 3, 2024: Endocrine Journal
#16
JOURNAL ARTICLE
Hanbing Guo, Kathleen E Malone, Susan R Heckbert, Christopher I Li
BACKGROUND: Preclinical evidence suggests improved breast cancer survival associated with statin use, but findings from observational studies are conflicting and remain inconclusive. The objective of this study was to assess the association between statin use after cancer diagnosis and cancer outcomes among breast cancer patients. METHODS: In this retrospective cohort study, 38,858 women aged ≥66 years who were diagnosed with localized and regional stage breast cancer from 2008 through 2017 were identified from the linked Surveillance, Epidemiology, and End Results Medicare database...
May 6, 2024: Cancer
#17
JOURNAL ARTICLE
D Koprulu, K Toprak, G Genc Tapar, M Ocak
OBJECTIVE: Primary percutaneous coronary intervention (pPCI) is the most effective reperfusion therapy in the treatment of ST-elevation myocardial infarction (STEMI). Although the infarct-related artery of STEMI patients is effectively revascularized during pPCI, effective reperfusion in the myocardial tissue may not be achieved. This condition is called the no-reflow (NR) phenomenon. FGF-21 is a circulating hormone-like molecule primarily secreted by the liver and has been proven to be the main metabolic regulator of glucolipid metabolism and insulin sensitivity...
April 2024: European Review for Medical and Pharmacological Sciences
#18
JOURNAL ARTICLE
Tansit Saengkaew, Suparb Aroonparkmongkol, Suttipong Wacharasindhu
BACKGROUND: Thailand has been administering the recombinant human growth hormone (rhGH) treatment for >20 years. Due to limited resources being available, efforts have been directed toward utilizing rhGH at the lowest feasible dose. However, there is currently a lack of evidence in terms of the efficacy and outcomes. OBJECTIVE: To evaluate the auxological outcomes of growth hormone (GH) treatment and the GH secretion ability after reaching final adult height (FAH) and discontinuing rhGH...
April 2024: Asian Biomedicine: Research, Reviews and News
#19
JOURNAL ARTICLE
Marcelo Antonini, Andre Mattar, Fernanda G Richter, Marcellus N Ramos, Marina D Teixeira, Nathalia N Pantarotto, Nadia F Matta, Andressa G Amorim, Denise J Pinheiro, Reginaldo C Lopes
PURPOSE: Neoadjuvant chemotherapy (NAC) can be used as upfront therapy in aggressive breast cancer (BC). human epidermal growth factor receptor 2 (HER2)-low BC, defined as tumors scoring +1 or +2 on immunohistochemistry without HER2 gene amplification by in situ hybridization, lacks information on real-world data (RWD) outcomes, especially in the NAC setting. This subgroup, which does not reach the HER2 positive criteria due to its lower receptor expression, represents a distinct clinical category potentially requiring tailored therapeutic approaches...
May 2024: Curēus
#20
JOURNAL ARTICLE
B Liu, Y Yuan, F Li, J B Li, L Bian, T Wang, S H Zhang, Z F Jiang
Objective: To evaluate the efficacy of chemotherapy and endocrine therapy combined with targeted drugs after progression on cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment in hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer. Methods: Patients with metastatic breast cancer diagnosed with HR positive/HER2 low expression at the Fifth Medical Center of PLA General Hospital from October 1, 2018 to September 30, 2023 were retrospectively included...
May 7, 2024: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
